CLOZAPINE INDUCED BLOOD DYSCRASIA IN PAKISTAN: A RETROSPECTIVE STUDY

Main Article Content

Dr Abdul Razzaque Nohri
Dr Parveen Channar
Dr Muhammad Sohail Baig
Dr Sidra Rehman
Dr Manisha Kumari
Dr Anum Farooqui

Keywords

Clozapine, Blood Dyscrasia, Adverse Events, Agranulocytosis, Schizophrenia

Abstract





Background: Clozapine is atypical antipsychotic particularly good at reducing the symptoms of schizophrenia, such as delusions and apathy. Despite being highly effective, the use of clozapine is limited due to the risk of blood disorders, known as blood dyscrasias. The objectives of the study were to determine how frequently clozapine-induced blood dyscrasia occur within study population, & outcomes associated with clozapine induced blood dyscrasia.


Methods: Medical data of patients was retrospectively reviewed in mentioned time period.  Before data collection, ethical approval was taken from Ethical Review Committee. The study excluded all OPD patients. Data collection was done using a pre-tested questionnaire that was adapted from a previous study. The sampling technique was non-probability convenience. The data was complied with proper coding in Microsoft Excel and then further analyzed in Statistical Package for Social Sciences for Windows (SPSS) version 29


Results: A total of 86 patients files were reviewed who were taking clozapine with or without other medicines. During the study period 23 patients (27%) developed blood dyscrasia. Out of which 64% were females. Majority of dyscrasia events happened in first three months (58%), followed by six months (31%), nine months (10%) and twelve months (1%). Among patients who developed blood dyscrasia most of the patients were diagnosed with with Scizophrenia and Bipolar Affective Disorder BAD (n =18, 67 %) followed by schizophrenia alone, BAD alone, drug induced psychosis, and schizophrenia plus agoraphobia. Out of 23 patients who developed blood dyscrasia 78% (n=18) patients were prescribed other medicines concomitantly with clozapine. The most commonly used drug was risperidone. Patients were also using valproate, and amlodipine/valsartan for the treatment of Epilepsy and Hypertension respectively. Majority (70%) adverse events were agranulocytosis.






Conclusion: Study emphasizes the critical need for diligent monitoring, especially in the early phases of clozapine treatment. Further research is needed to explore determinants for incidence and strategies for reducing the incidence of blood dyscrasia in patients taking clozapine. Future research should aim to identify predictive markers for these adverse effects to enhance patient safety and treatment efficacy.

Abstract 53 | PDF Downloads 24

References

1. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2009; 18; 39-60
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
3. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Siskind D, McCartney L, Goldschlager R, Kisely S. Br J Psychiatry. 2016;209:385–392.
4. Clozapine-induced agranulocytosis. Mijovic A, MacCabe JH. Ann Hematol. 2020;99:2477–2482
5. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Li XH, Zhong XM, Lu L, et al. Psychol Med. 2020;50:583–594.
6. Abanmy NO, Al-Jaloud A, Al-Jabr A, Al-Ruwaisan R, Al-Saeed W, Fatani S. Clozapine-induced blood dyscrasias in Saudi Arab patients. Int J Clin Pharm. 2014 Aug;36(4):815-20. doi: 10.1007/s11096-014-9967-0. Epub 2014 Jun 12. PMID: 24917217.
7. J. Modestin, D. Dal Pian, P. Agarwalla Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records J. Clin. Psychiatry, 66 (4) (2005), p. 3023
8. D. Miller Del Review and management of clozapine side effects J. Clin. Psychiatry, 61 (suppl 8) (2000), p. 18308
9. S. Ghaznavi, M. Nakic, P. Rao, et al.Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia Am. J. Psychiatry, 165 (7) (2008), pp. 813-818
10. Clozapine-induced agranulocytosis. Mijovic A, MacCabe JH. Ann Hematol. 2020;99:2477–2482.
11. M. Çetin, S. Köse Klozafobik tutumlara karşı güncellenmiş klozapin ile tedavi kılavuzu J. Mood Disord. (JMOOD), 6 (4) (2016), pp. 242-255
12. A. Mijovic, J.H. MacCabe Clozapine-induced agranulocytosis Ann. Hematol., 99 (11) (2020), pp. 2477-2482
13. Atkin K, Kendall F, Gould D, Freeman H, Lieberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-8.
14. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255-63
15. Paribello P, Manchia M, Zedda M, Pinna F, Carpiniello B. Leukocytosis Associated with Clozapine Treatment: A Case Series and Systematic Review of the Literature. Medicina. 2021; 57(8):816. https://doi.org/10.3390/medicina57080816
16. Taipale, H.; Tanskanen, A.; Mehtälä, J.; Vattulainen, P.; Correll, C.U.; Tiihonen, J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020, 19, 61–68.
17. Tiihonen, J.; Mittendorfer-Rutz, E.; Majak, M.; Mehtälä, J.; Hoti, F.; Jedenius, E.; Enkusson, D.; Leval, A.; Sermon, J.; Tanskanen, A.; et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients with Schizophrenia. JAMA Psychiatry 2017, 74, 686–693.
18.Nohri AR, Siddiqui MI, Usman G, Sarang S, MemonHQ, Singh D, Kumar S. Antibiotic dispensation without prescription by community pharmacies in Pakistan. Journal of Medicine, Surgery, and Public Health. 2024 Feb9:100065.
19. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian Journal of Psychological Medicine. 2013;35(2):121. doi:https://doi.org/10.4103/0253-7176.116232
20. Abanmy NO, Al-Jaloud A, Al-Jabr A, Al-Ruwaisan R, Al-Saeed W, Fatani S. Clozapine-induced blood dyscrasias in Saudi Arab patients. Int J Clin Pharm. 2014 Aug;36(4):815-20. doi: 10.1007/s11096-014-9967-0. Epub 2014 Jun 12. PMID: 24917217.
21. Dell'Osso B, Cafaro R, Ketter TA. Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies. Int J Bipolar Disord. 2021 Jan 4;9(1):3. doi: 10.1186/s40345-020-00207-z. PMID: 33392912; PMCID: PMC7779377.
22. Alberich S, Fernández-Sevillano J, González-Ortega I, Usall J, Sáenz M, González-Fraile E, González-Pinto A. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. Psychiatry research. 2019 Oct 1;280:112506.
23. Mahmood T, Silverstone T, Spittle B. Risperidone appears safe in patients with antipsychotic-induced blood dyscrasias. Int Clin Psychopharmacol. 1996 Mar;11(1):53-4. doi: 10.1097/00004850-199603000-00007. PMID: 8732314.
24. Grover S, Shouan A, Chakrabarti S, Avasthi A. Haematological side effects associated with clozapine: A retrospective study from India. Asian J Psychiatr. 2020 Feb;48:101906. doi: 10.1016/j.ajp.2019.101906. Epub 2019 Dec 13. PMID: 31865196.

Most read articles by the same author(s)